#USA #Palo Alto #Kodiak Sciences #KSI-501 #Zenkuda

Kodiak Sciences to Unveil Results from Pivotal Phase 3 Study

Overview
Kodiak Sciences Inc., a biotechnology firm primarily focused on retinal therapies, is gearing up to reveal the topline results of its pivotal Phase 3 study, DAYBREAK, on September 28, 2026. This critical research evaluates two promising treatments, Zenkuda™ (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer), for patients suffering from wet age-related macular degeneration (AMD).

What is Wet Age-Related Macular Degeneration?
Wet AMD is a severe eye disorder that leads to significant vision loss in older adults. It occurs when abnormal blood vessels grow under the retina, disrupting its regular functionality. Early medical intervention is crucial to stabilize vision and prevent further deterioration. Traditional treatments, including anti-VEGF therapies, have been the standard approach to manage this condition.

Webcast Announcement
Kodiak will conduct a webcast on the same day at 8:30 AM Eastern Time. Interested parties can tune in via the DAYBREAK Topline Results Webcast, where they will be able to access live updates and insights from the study. For those unable to join live, an archived version of the webcast will be made available for a limited period.

Company Commitment to Innovation
Kodiak Sciences is committed to revolutionizing the treatment of retinal diseases and is developing a portfolio of cutting-edge therapies. The company has a strong focus on creating solutions that target the most prevalent causes of blindness worldwide. In addition to Zenkuda and KSI-501, Kodiak is also working on KSI-101, a bispecific protein that is part of two ongoing Phase 3 trials.

Market Significance
The treatments under examination have a substantial market potential, targeting the lucrative $15 billion anti-VEGF market associated with retinal vascular disorders. With the rising prevalence of wet AMD and diabetic retinal complications, the need for innovative and effective treatments is more pressing than ever.

Looking Ahead
As Kodiak prepares to disclose the results from the DAYBREAK study, stakeholders are eager to evaluate the therapeutic efficacy and safety profiles of Zenkuda and KSI-501. The information revealed will be vital not only for the company's future but also for millions of patients battling this debilitating condition.

In conclusion, as September 28 approaches, the industry watches closely, anticipating groundbreaking findings that could reshape the landscape of wet AMD treatment. Kodiak Sciences is destined to inspire hope in a domain where effective treatments are crucial. Stay tuned for updates and insights from the REP, which will reveal the findings on this pivotal journey.

About Kodiak Sciences Inc.
Based in Palo Alto, California, Kodiak Sciences is at the forefront of providing innovative solutions for retinal diseases, venturing into late-stage clinical programs designed to change how we approach preventing vision loss globally. With a dedicated scientific team and a passion for improving patients' lives, Kodiak is a name that resonates throughout the field of biomedicine today.

For more information on Kodiak Sciences and its various initiatives, visit their official website.